Hew Quon, MD
Internal Medicine · Los Angeles, CANPI 1710074026
Payments from drug & device makers
Across 810 payments — averaging $35.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$13K
- AstraZeneca$4K
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$806
- Novartis$780
- plus $8K from 30 others
What the payments were for
- Consulting fees$9323%
- Speaking & faculty fees$11,81342%
- Food & beverage$15,49355%
- Education$1581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 48 | $13,027 |
| AstraZeneca | 128 | $3,620 |
| Boehringer Ingelheim | 68 | $1,368 |
| Novo Nordisk | 73 | $1,105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 46 | $806 |
| Novartis | 44 | $780 |
| GSK | 38 | $776 |
| AbbVie(2 entities) | 55 | $764 |
| Amgen(2 entities) | 26 | $669 |
| Bayer | 22 | $622 |
| Lilly USA, LLC | 31 | $590 |
| Gilead | 25 | $521 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $485 |
| Esperion Therapeutics, Inc. | 18 | $417 |
| Merck | 18 | $393 |
| Ironwood Pharmaceuticals, Inc | 22 | $342 |
| Johnson & Johnson | 16 | $300 |
| Avanir Pharmaceuticals, Inc. | 20 | $242 |
| Sunovion Pharmaceuticals Inc. | 15 | $240 |
| E.r. Squibb & Sons, L.L.C. | 14 | $175 |
| Aimmune Therapeutics, Inc. | 6 | $162 |
| Radius Health, Inc. | 8 | $157 |
| Pfizer | 10 | $155 |
| Sanofi-aventis U.S. LLC | 8 | $128 |
| Vifor Pharma, Inc. | 4 | $91 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Scilex Pharmaceuticals Inc. | 3 | $68 |
| Corium, LLC | 2 | $63 |
| Lundbeck LLC | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 1 | $30 |
| Astellas Pharma US Inc | 2 | $24 |
| Genentech USA, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $17 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,395 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 1,242 | $1,336,400 |
| FarxigaDapagliflozin Propanediol | 1,184 | $1,156,735 |
| VascepaIcosapent Ethyl | 2,282 | $1,125,763 |
| KerendiaFinerenone | 708 | $707,500 |
| Diclofenac Sodium | 1,066 | $562,770 |
| TradjentaLinagliptin | 444 | $454,184 |
| EntrestoSacubitril/Valsartan | 362 | $436,293 |
| LinzessLinaclotide | 323 | $303,652 |
| NeuproRotigotine | 297 | $264,939 |
| RybelsusSemaglutide | 162 | $238,834 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 337 | $231,711 |
| EliquisApixaban | 234 | $208,656 |
| Roflumilast | 908 | $208,607 |
| JentaduetoLinagliptin/Metformin Hcl | 244 | $207,852 |
| TrulicityDulaglutide | 190 | $201,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Glyxambi, Jentadueto Xr | $1,368 | $2,346,9382,320 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,620 | $1,251,5631,314 claims |
| BayerKerendia | $622 | $707,500708 claims |
| NovartisEntresto | $780 | $436,293362 claims |
| AbbVieLinzess, Creon | $764 | $362,924372 claims |
| Novo NordiskRybelsus, Ozempic | $1,105 | $327,631233 claims |
| MerckJanumet, Januvia, Janumet Xr | $393 | $265,108269 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $590 | $258,941242 claims |
| GSKTrelegy Ellipta | $776 | $231,711337 claims |
| PfizerEliquis | $155 | $208,656234 claims |
| AmgenProlia | $669 | $162,06394 claims |
| Johnson & JohnsonProcrit | $300 | $113,289104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.